DISSOLUTION METHOD DEVELOPMENT AND VALIDATION FOR DERACOXIB CHEWABLE TABLET USING UV SPECTROPHOTOMETRIC METHOD
AbstractDeracoxib is a coxib class of Non Steroidal Anti-Inflammatory Drug (NSAID). Like other NSAIDs, its effects are caused by inhibition of Cyclooxygenase (COX) enzymes. Deracoxib causes greater inhibition of COX-2 than of COX-1. The aim of this proposed method was to develop and validate the UV spectrophotometric method for the routine quality control check of API containing 25 mg Deracoxib intablets dosage form. To investigate the most preferable dissolution method includes dissolution media as pH 6.8 sodium phosphate buffer + 1 % Sodium Lauryl Sulphate, 900ml, temperature as 37±0.5°C, RPM as 75, time 45 min. The absorbance maximum of Deracoxib was found to be 255nm. The concentration range of the proposed method was 5-15µg/ml and linearity as r2 = 0.9959.The result of intraday &interday precision was 0.1458% and 0.1214% RSD respectively. The results of the percentage recoveries were 99.2%, 99.3%, and 99.1%. The effective dissolution method was developed and validated by UV spectrophotometer which used to be more applicable in various pharmaceutical industries.
Article Information
58
1834-1838
701
823
English
IJPSR
M. Dhoru *, Y. Chandekar and K. Detholia
Department of Quality Assurance, Smt. S. M. Shah Pharmacy College, Mahemdavad, Gujarat, India.
minu.pharm@gmail.com
10 March 2019
06 December 2019
23 December 2020
10.13040/IJPSR.0975-8232.12(3).1834-38
01 March 2021
Download